Instrument Inactif

Communiqués STADA Arzneimittel CBOE EUROPE EQUITIES

Actions

0OM4

DE0007251803

Cours en clôture CBOE EUROPE EQUITIES Autres places de cotation
- ^EUR	-

2023	Alvotech et Stada obtiennent le soutien du comité de l'UE pour le biosimilaire de Stelara	MT
2021	Sanofi cède 16 produits de santé grand public à l'allemand Stada	DJ

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo[®] for the treatment of IgA nephropathy	30/05	AQ
Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK	29/05	AQ
Xbrane and STADA partner with Valorum Biologics to commercialize ranibizumab biosimilar candidate in the US	10/05	AQ
Xbrane has received additional subscription undertakings corresponding to approximately SEK 18.1 million in the Company's rights issue	04/03	AQ
Calliditas announces filing with UK MHRA for Kinpeygo in IgA nephropathy	03/10/23	AQ
STADA and Calliditas announce the filing for full marketing authorization of Kinpeygo® in the EU	28/09/23	AQ
Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet	15/08/23	AQ
STADA and Xbrane weigh options for ranibizumab biosimilar candidate	25/07/23	AQ
Xbrane announce U.S. FDA filing acceptance for a Lucentis® (ranibizumab) biosimilar candidate	21/06/23	AQ
STADA AND XBRANE LAUNCH XIMLUCI AS RANIBIZUMAB BIOSIMILAR IN GERMANY	26/05/23	AQ
STADA and Xbrane launch Ximluci® as ranibizumab biosimilar in Germany	26/05/23	AQ
STADA AND XBRANE SUPPLY XIMLUCI IN ENGLAND UNDER NHS CONTRACT	26/04/23	AQ
STADA and Xbrane supply Ximluci® (ranibizumab) in England under NHS contract	25/04/23	AQ
STADA and Xbrane launch ranibizumab to support patient access in Europe	03/04/23	AQ
AFR: STADA Arzneimittel AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]	23/02/23	EQ
AFR: STADA Arzneimittel AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]	23/02/23	EQ
European Biosimilar Regulatory Updates	08/02/23	AQ
Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathy	02/02/23	AQ
STADA and Xbrane obtain British approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®	17/01/23	AQ
STADA And Xbrane Announce Approval Of Ranibizumab Biosimilar In Europe	15/11/22	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués STADA Arzneimittel CBOE EUROPE EQUITIES

Actions

0OM4

DE0007251803

Communiqués

Filtres